IVDD to IVDR Transition Guide: Critical Challenges for IVD Manufacturers

The Regulatory Shift That’s Reshaping IVD Manufacturing

The European IVD industry is undergoing a regulatory revolution. After years under the relatively straightforward In Vitro Diagnostic Directive (IVDD), manufacturers now face the much more rigorous In Vitro Diagnostic Regulation (IVDR). The impact is dramatic: where once 80% of IVD products could be self-certified without notified body involvement, now around 80% require third-party oversight and certification.

For manufacturers, familiar pathways to market have vanished. Products with established technical files suddenly need extensive new documentation, added clinical evidence, and formal notified body approval.

      This is not just increased paperwork—it’s a fundamental business challenge changing development timelines, market strategy, and even which products remain viable in Europe.
    

Why the IVDR Transition Matters to Your Business

Significant increase in regulatory oversight, requiring more resources and expertise
Higher development and maintenance costs due to extra testing & documentation
Longer time-to-market with notified body review bottlenecks
Portfolio rationalization: Some legacy products may not justify IVDR compliance investment

“We’ve had to completely restructure our regulatory department and significantly grow our documentation team just to handle IVDR. Products that took 6 months to bring to market now take 18-24 months due to notified body backlogs.” — IVD manufacturer client

Understanding the IVDR Classification System: The Foundation of Your Transition Strategy

The new rule-based classification system (Classes A, B, C, D; D=highest risk) determines your clinical evidence, documentation, and required notified body involvement.

      Accurately classifying your products under IVDR is the essential first step of any transition strategy.
    

Portfolio Reality: One diagnostic test maker discovered all 12 of their formerly self-certified IVDD assays now required notified body under IVDR—8 in Class C, 4 in Class B.

What Has Changed? IVDD vs. IVDR

Clinical Evidence & Performance Evaluation

Under IVDD: Minimal requirements; literature and analytical data often sufficient
Under IVDR: Need a Performance Evaluation Plan (PEP), Scientific Validity Report, Analytical Performance Report, Clinical Performance Report, and comprehensive Performance Evaluation Report (PER)

      Manufacturers must collect, analyze, and document much more clinical data; for many, new studies are required, causing major delays.
    

Technical Documentation

More comprehensive: risk management, verification/validation data, post-market performance, benefit-risk analysis, software validation (if applicable)
Requires restructuring technical files and creating new documents/data systems

Post-Market Surveillance & Vigilance

Now includes proactive data collection (not just adverse events)
Requires regular PMPF, PSURs, SSP (for higher-risk devices)

      Ongoing requirements replace IVDD’s more reactive approach with proactive surveillance.
    

The Timeline Challenge: Meeting IVDR Deadlines

Phased transition timelines provide some relief, but the underlying bottleneck remains—there are far fewer notified bodies than needed. Only 30-40% of demand for IVDR certifications may be met with current capacity.

Expert Insight: “The most critical challenge isn’t technical—it’s simply booking notified body appointments. Wait times of 12-18 months for initial consultation are forcing tough portfolio decisions.”

Certification Challenge: Manufacturers must strategically prioritize products for transition, sometimes discontinuing legacy items based on market value versus certification cost.

Common Misunderstanding: “We Can Just Update Our Existing Documentation”

Transitioning usually requires a full redesign of your QMS and documentation, not just updating old files. Performance evaluation is now an entirely new structure focused on scientific validity, analytical performance, and clinical performance.

A company estimated a 6-month transition based on reusing files; after a gap analysis, they needed 18-24 months for compliant documentation and new clinical studies.

The Critical Decision Point: Gap Analysis & Transition Planning

Begin with a comprehensive gap analysis including:

Reclassification impact for each product
Additional required clinical evidence
How your documentation structure must evolve
Quality system (QMS) modification needs
Post-market surveillance and vigilance system updates

      Most manufacturers discover 70–80% of existing documentation needs significant rework or total replacement for IVDR.
    

Case Study: A Successful IVDR Transition

Scenario: Medium manufacturer, 15 products, estimated €100k–€150k per product for IVDR compliance.

Actions:
– Detailed portfolio analysis to prioritize by value & complexity
– Phased submission, starting with highest-value products
– Early engagement with notified body for timely assessment
– Dedicated documentation team & clinical evidence strategy

Result: Top five products transitioned before the IVDR deadline; the rest progressing. Market access maintained for priority products. Strategic approach balanced costs and compliance.

Preparation Strategy: Your IVDR Transition Roadmap

Classify your full portfolio under IVDR
Conduct a gap analysis for technical documentation & clinical evidence
Engage with notified bodies early to secure assessment slots
Build a risk-based timeline, focusing first on highest value/gap products
Implement IVDR-compliant documentation templates/processes
Train team members on IVDR and new templates/tools
Outsource specialized needs (e.g., clinical evidence generation) if helpful

      The transition is your opportunity to improve not just compliance, but product documentation, clinical quality, and your market position.
    

Conclusion: Turning Regulatory Challenge into Competitive Advantage

The IVDD to IVDR transition presents formidable challenges, but also strategic opportunity. Manufacturers approaching this proactively will enjoy robust systems, stronger clinical evidence, and an advantage as competitors struggle. Extended timelines buy time—but the notified body capacity bottleneck makes early action crucial.

Start now: Gap analysis, realistic planning, and experienced support can transform IVDR from a burden into a competitive edge.

Have questions? Contact us at (770) 518-9967 or info@enhancequality.com

Standard Overview